arrow
C

Craig M. Goodwin

University of North Carolina at Chapel Hill
H指数:15
被引数:1,650

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Science
IF45.8
2024-01-010
OA
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

联合CDK4/6抑制剂治疗KRAS突变型胰腺癌

2022-11-0857
OA
Functional and biological heterogeneity of KRASQ61 mutations

KRASQ61突变的功能和生物学异质性

2022-08-0915
OA
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma

同时抑制ERK和法尼基转移酶抑制HRAS突变型头颈部鳞状细胞癌的生长

2022-02-2814
OA
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

CHK1保护致癌KRAS表达细胞免受DNA损伤,是胰腺癌治疗的靶点

2021-11-0123
OAAI
Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

靶向p130Cas-and微管依赖的MYC调节使胰腺癌对ERK MAPK抑制敏感

2021-06-0118
OAAI
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Raf-mek-erk级联的低剂量垂直抑制导致KRAS突变型癌症的凋亡死亡

2020-06-0171
OAAI
REPLY TO TRAN ET AL.: Dimeric KRAS protein-protein interaction stabilizers
2020-02-1113
OAAI
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

非典型KRASG12R突变体在胰腺癌的PI3K信号传导和巨胞饮作用中受损

2020-01-09139
OAAI
Drugging an undruggable pocket on KRAS

在KRAS上给一个不可下药的口袋下药

2019-07-22314
OAAI
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors
2016-12-1961
OAAI